Henrik Agersí¸

Henrik Agersí¸

Novo Nordisk A/S - Bagsvaerd / Denmark
Others
AD Scientific Index ID: 4433053
-
person_outline Henrik Agersí¸'s MOST POPULAR ARTICLES
1-) Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administrationLB Knudsen, PF Nielsen, PO Huusfeldt, NL Johansen, K Madsen, ...Journal of medicinal chemistry 43 (9), 1664-1669, 20009182000
2-) The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy menH Agersø, LB Jensen, B Elbrønd, P Rolan, M ZdravkovicDiabetologia 45, 195-202, 20026302002
3-) Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjectsT Vilsbøll, H Agersø, T Krarup, JJ HolstThe Journal of Clinical Endocrinology & Metabolism 88 (1), 220-224, 20035642003
4-) Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjectsB Elbrønd, G Jakobsen, S Larsen, H Agersø, LB Jensen, P Rolan, J Sturis, ...Diabetes care 25 (8), 1398-1404, 20023722002
5-) Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetesCB Juhl, M Hollingdal, J Sturis, G Jakobsen, H Agersø, J Veldhuis, ...Diabetes 51 (2), 424-429, 20023702002